TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03419845

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Step Right Buddy
Description: The Step Right Buddy, which is under investigation in this clinical study, is an elasticated band that attached by Velcro to the back legs of a standard walking frame. The purpose of the Step Right Buddy is to provide sensory feedback to standard walking frame users of how far to step in to the frame and to encourage them to move the frame forward.
Study: NCT04181957

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Participants take one dose of placebo (lactose) tablet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisdexamfetamine Dimesylate
Description: Participants take one 50mg tablet of lisdexamfetamine dimesylate once.
Study: NCT00784082

Intervention type: DRUG
Intervention: Hydroxycarbamide, Hydroxyurea (drug)
Description: hydroxyurea 20-25 mg/kg/day since at least 3 months

Intervention type: DRUG
Intervention: Hydroxycarbamide, Hydroxyurea (drug)
Description: hydroxyurea 20-25 mg/kg/day since at least 3 months
Study: NCT04884945

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Pyeloplasty (OP)
Description: Open approach for the surgical correction of UPJ obstruction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic-Assisted Laparoscopic Pyeloplasty (RALP)
Description: Robotic approach with the da Vinci Surgical System for the surgical correction of UPJ obstruction
Study: NCT00656760

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: PET/CT is being performed on all patients in the study.
Study: NCT02021851

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone and aprepitant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone and ondansetron
Study: NCT00614991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: 400mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: 400mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: 400mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: 400mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: 400mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: 400mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosamprenavir
Description: 1400mg BID, 700 mg BID or 1400 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosamprenavir
Description: 1400mg BID, 700 mg BID or 1400 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosamprenavir
Description: 1400mg BID, 700 mg BID or 1400 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosamprenavir
Description: 1400mg BID, 700 mg BID or 1400 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosamprenavir
Description: 1400mg BID, 700 mg BID or 1400 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosamprenavir
Description: 1400mg BID, 700 mg BID or 1400 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: 100 mg BID or QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: 100 mg BID or QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: 100 mg BID or QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: 100 mg BID or QD
Study: NCT03122197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 50 mg/m2 TMZ administered orally once daily
Study: NCT02067468

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HPV test
Description: QIAGEN - The Digene HPV test®

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: COLPOSCOPY
Description: Colposcopy routine health services

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: COLPOSCOPY
Description: Colposcopy routine health services

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: COLPOSCOPY
Description: Colposcopy routine health services

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cytology
Description: Cytology routine health services
Study: NCT03753763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide Methanesulfonate
Description: 100 mg (free base)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Safinamide Methanesulfonate matching placebo
Description: 100 mg placebo
Study: NCT04330716

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Genetic Counseling
Description: Standard of care genetic counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Video
Description: Video tutorial about genetic testing
Study: NCT03139227

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bio specimen Collection
Description: Patients undergo collection of blood and urine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Consume celery-banana bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00901862

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed magnetic fields (Quantum MH-2MR bracelet)
Description: Pulsed magnetic fields

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham pulsed magnetic fields (Quantum MH-2MR bracelet)
Description: Hybrid circuits crucial for the generation of the electromagnetic field had been removed.
Study: NCT03587922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fantom
Description: Treatment of den ovo coronary lesions
Study: NCT05440487

Intervention type: OTHER
Intervention: Iron chelator
Description: There is no treatment allocation. Patients administered approved Iron chelators by prescription that have started before inclusion of the patient into the study will be enrolled.
Study: NCT03366597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: 1.5%-3% Sevoflurane will be given during the cardiac surgery except cardiopulmonary bypass.
Study: NCT02420990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Integration Protocol (MIP)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Changing Academic Support in the Home for Adolescents with ADHD (CASH-AA)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Changing Academic Support in the Home for Adolescents with ADHD (CASH-AA)
Study: NCT05300854

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard anesthesia in addition to serratus plane block
Description: a US-guided SPB was performed after induction of general anesthesia with the patient lying supine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard anesthesia in addition to para-vertebral block
Description: Standard anesthesia in addition to para-vertebral block
Study: NCT05620069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music listening
Description: Participants are asked to select one of four music playlists and listen to it for appr. 30 minutes at bedtime during the intervention period.
Study: NCT03197350

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: cMR
Description: cardiac MRI done to complete the diagnosis

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: cMR
Description: cardiac MRI done to complete the diagnosis

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: cMR
Description: cardiac MRI done to complete the diagnosis

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: biomarker
Description: Biomarker correlation with cMR parameters Prognostic information

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: biomarker
Description: Biomarker correlation with cMR parameters Prognostic information

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: biomarker
Description: Biomarker correlation with cMR parameters Prognostic information
Study: NCT02835898

Intervention type: OTHER
Intervention: Conventional periodontal treatment
Description: Conventional routine periodontal treatment will be done for patients in test group
Study: NCT01480232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-6124
Description: One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-6124
Description: One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: One placebo capsule ingested orally daily for 12 weeks (84 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Capsule
Description: One placebo capsule ingested orally daily for 12 weeks (84 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NicoDerm Patch (Active)
Description: One NicoDerm patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NicoDerm Patch (Active)
Description: One NicoDerm patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRT Patch (Placebo)
Description: One NRT patch (Placebo) daily for first 6 weeks (42 days).
Study: NCT03990597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Applied topically
Study: NCT01480232

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NRT Patch (Placebo)
Description: One NRT patch (Placebo) daily for first 6 weeks (42 days).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Supportive and Behavioral Treatment
Description: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Supportive and Behavioral Treatment
Description: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Brief Supportive and Behavioral Treatment
Description: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Supportive and Behavioral Treatment
Description: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.
Study: NCT02349204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music - Mozart's sonata for 2 pianos in D-440
Study: NCT02918539

Intervention type: DRUG
Intervention: florbetapir F 18 PET scan
Description: For those patients who do not have an existing amyloid scan, each will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 followed by a Positron Emission Tomography (PET) Scan to determine amyloid status
Study: NCT01461824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA)
Description: 75mg, 104mg and 150mg DMPA, IM, every 12 weeks for 12 months
Study: NCT03990597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wound Dressing Material
Description: Applied StrataXRT topically
Study: NCT00581087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA treatment
Description: DHEA : 200 mg/day hard gelatine capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment : 200 mg/day hard gelatine capsule
Study: NCT03262038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: This arm will receive (in a blinded fashion) 0.1 mg/kg of Ondansetron IV made up to 5 mLs intra-operatively and Ondansetron IV 0.1 mg/kg made up to 5 mLs every 6 hours for 24 hours postoperatively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: This arm will receive (in a blinded fashion) a volume-matched placebo intraoperatively as well as IV every 6 hrs for 24 hours postoperatively.
Study: NCT01461824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depot medroxyprogesterone acetate (DMPA)
Description: 75mg, 104mg and 150mg DMPA, IM, every 12 weeks for 12 months
Study: NCT03872934

Intervention type: BEHAVIORAL
Intervention: implant anxiety
Description: to determine the type of music that reduces anxiety in patients undergoing implant surgery.

Intervention type: BEHAVIORAL
Intervention: implant anxiety
Description: to determine the type of music that reduces anxiety in patients undergoing implant surgery.

Intervention type: BEHAVIORAL
Intervention: implant anxiety
Description: to determine the type of music that reduces anxiety in patients undergoing implant surgery.

Intervention type: BEHAVIORAL
Intervention: implant anxiety
Description: to determine the type of music that reduces anxiety in patients undergoing implant surgery.
Study: NCT04311372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Sesssion+Material+Videos
Description: n =50 participants (Educational Session + Material from Educational Session (Handout form) + Access to Online Video Library)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Sesssion+Material ONLY
Description: n =50 participants (Educational Session + Material from Educational Session (Handout form) ONLY)
Study: NCT00985179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Description: Employees in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of them
Study: NCT04605224

Intervention type: BEHAVIORAL
Intervention: Culinary class
Description: This hands-on, optional course teaches students how to measure and weigh ingredients, read and follow recipes, apply various food preparation, cooking and assembly techniques, as well as prepare meals, as per the provincial curriculum
Study: NCT01333774

Intervention type: DRUG
Intervention: Glucobay (Acarbose, BAYG5421)
Description: Patients treated with acarbose tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
Study: NCT04695236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZOLL Intravascular Temperature Management system, Quattro catheter
Description: ZOLL Intravascular Temperature Management system, Quattro catheter

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Treatment
Description: Standard Treatment for Ischemic Strokre
Study: NCT02353689

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low FODMAP
Description: consumed EN formula containing low FODMAPs (0.320g/can) during 14-day intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: moderate FODMAP
Description: consumed EN formula containing moderate FODMAPs (0.753g/can) during 14-day intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high FODMAP
Description: consumed EN formula containing high FODMAPs (1.222g/can) during 14-day intervention
Study: NCT04409626

Intervention type: OTHER
Intervention: Plasma sodium level (continuous variables)
Description: Observational study, so the exposures of interest (5-year mean and minimum plasma sodium) are not administered to the patients. Ultimately, our interest is in hyponatraemia.

Intervention type: OTHER
Intervention: Plasma sodium level (continuous variables)
Description: Observational study, so the exposures of interest (5-year mean and minimum plasma sodium) are not administered to the patients. Ultimately, our interest is in hyponatraemia.
Study: NCT03328078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be provided as a tablet or capsule dosage form to be taken QD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be provided as a tablet or capsule dosage form to be taken QD.
Study: NCT03140124

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Each participant will be provided with an ActiveLife Trainer to use during visit 2 or 3. The ActiveLife Trainer is a stationary pedaling machine that one can use while seated. It was designed to be used while working and makes very little noise. It is a safe, low-impact physical activity machine with adjustable resistance. The machine communicates via Bluetooth with the Wahoo Fitness app which records activity metrics such as distance cycled. Participants will be provided with a tablet on which the Wahoo Fitness app will track their exercise during the session. The ActiveLife Trainer has been used in numerous research studies (Carr et al., 2014; Botter et al., 2013; Burford et al., 2013; Carr et al., 2013).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Each participant will be provided with an ActiveLife Trainer to use during visit 2 or 3. The ActiveLife Trainer is a stationary pedaling machine that one can use while seated. It was designed to be used while working and makes very little noise. It is a safe, low-impact physical activity machine with adjustable resistance. The machine communicates via Bluetooth with the Wahoo Fitness app which records activity metrics such as distance cycled. Participants will be provided with a tablet on which the Wahoo Fitness app will track their exercise during the session. The ActiveLife Trainer has been used in numerous research studies (Carr et al., 2014; Botter et al., 2013; Burford et al., 2013; Carr et al., 2013).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Worry Stone
Description: For the worry stone condition, both the participants will rub a stone for the duration of the session. Each participant will be provided with a worry stone to rub during visit 2 or 3. These are small sooth stones that fit in the palm of one's hand.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Worry Stone
Description: For the worry stone condition, both the participants will rub a stone for the duration of the session. Each participant will be provided with a worry stone to rub during visit 2 or 3. These are small sooth stones that fit in the palm of one's hand.
Study: NCT04921657

Intervention type: DRUG
Intervention: Rosuvastatin 10mg
Study: NCT00502619

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: A specific regimen of acupuncture sites will be needled twice weekly for eight weeks and once weekly for a subsequent eight weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill Exercise
Description: After the first four weeks of acupuncture treatments, subjects will initiate a three times per week treadmill program, which will continue for a total of 12 weeks in conjunction with the acupuncture treatments.
Study: NCT02983513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Intervention
Study: NCT03940456

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire mainly focusing on low back pain, pain related disorders, psychosocial factors and the use of alternative treatments for pain
Study: NCT00520299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI PEG 20
Description: Intramuscular injections were administered into the deltoid, gluteal, or quadricep muscles once weekly (± 2 days) for 9 weeks during cycle 1 and 8 weeks during subsequent cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI PEG 20
Description: Intramuscular injections were administered into the deltoid, gluteal, or quadricep muscles once weekly (± 2 days) for 9 weeks during cycle 1 and 8 weeks during subsequent cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI PEG 20
Description: Intramuscular injections were administered into the deltoid, gluteal, or quadricep muscles once weekly (± 2 days) for 9 weeks during cycle 1 and 8 weeks during subsequent cycles
Study: NCT00136357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Skills Groups
Description: 12 week mind-body skills group program including guided imagery, relaxation techniques,autogenic training, meditation, biofeedback, drawings, genograms and movement techniques.
Study: NCT02121314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous administration of 1st line TB drugs, day 1
Description: TB drugs IV on day 1 for calculation of bioavailability while fasting or fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous administration of 1st line TB drugs, day 1
Description: TB drugs IV on day 1 for calculation of bioavailability while fasting or fed
Study: NCT01833806

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate MRgFUS
Description: Focused Ultrasound Ablation
Study: NCT01468038

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: active trazodone and sentra pm-like placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sentra PM
Description: Active Sentra PM and trazodone-like placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sentra PM and Trazodone (CoPack Kit Trazamine)
Description: A CoPack Kit - Trazamine, consisting of the co-administration of Sentra PM and trazodone.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo trazodone and placebo Sentra PM
Description: Trazodone-like placebo and Sentra PM-like placebo co-administered as placebo of Trazamine CoPack Kit.
Study: NCT02724111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sufficient dose of rocuronium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex 10 min after position change
Study: NCT03880006

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case management
Description: Case management intervention is a multi-step process to coordinate care and provide a family-like support system for people living with HIV. Individuals are assigned to a specific case manager who will provide support throughout the study. The case management approach has five key components: 1) initial meeting between person living with HIV and case manager; 2) follow up meeting between case manager and participant; 3) biweekly automatic text messages sent to participant; 4) monthly phone calls from case manager; and 5) face-to-face meetings between case manager and participant every 6 months.